Prophylactic Anthrax Toxin Vaccine

预防性炭疽毒素疫苗

• 批准号: 6555347
• 负责人: PETER M. HOBART
• 金额: $ 46.29万
• 依托单位: VICAL, INC.
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-07-01 至 2003-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6555347
• 关键词: Bacillus anthracis; active immunization; anthrax; anthrax vaccines; bacterial toxins; bioterrorism /chemical warfare; gene delivery system; laboratory mouse; laboratory rabbit; lethal genes; nonhuman therapy evaluation; plasmids; spores; vaccine development; vector vaccine

DESCRIPTION (provided by applicant): This STTR grant proposal is for the development of a safe and efficacious Anthrax Toxin Vaccine. The present world-wide threat of the use of anthrax spores as a bioterrorist weapon in military theaters as well as on the general population has focused attention on the need for a more effective vaccine against anthrax. The recognition during the past few months that few members of the medical community have seen an anthrax infection in humans and therefore only a very few are equipped to diagnose and treat anthrax. The availablity of a safe and efficacious prophylactic vaccine would effectively neutralize this form of bioterrorist threat. Price, et al., have shown that a vaccine comprised of plasmid DNAs encoding detoxified protective antigen (PA) and lethal factor (LF) protects mice from an intravenous challenge using 5X the lethal dose of toxic protein. Based on this work and subsequent work (presented here) showing that a similar DNA vaccination protocol can protect rabbits from a more rigorous spore inhalation challenge, this grant proposes the pre-clincal work required to support testing of a DNA vaccine in human clinical trials. The work would advance an FDA approved plasmid DNA vector encoding the the PA or LF plasmids or a formulation combining the PA + LF plasmids through a series of experimental protocols to demonstrate the generation of a protective immunne response in both mice and rabbits. The thrust of this proposal is to determine the best plasmid to deliver these coding sequences, the best formulation for intramuscular delivery, and the best injection regime and dosage for achieving protection in a large mammal This work demonstrates the best use of STTR funding. It brings together Vical, the company which has advanced DNA vaccination technology over the past 12 years and holds the intellectural property required to make DNA vaccines commercial products, with Dr. Darrell Galloway, a professor at Ohio State University and a researcher who has advanced the use of DNA vaccines against anthrax. The proposal also presents how the combined efforts of an academic laboratory with the expertise, animal facilities, and reagents required for these pre-clinical experiments and a small biotechnology company expert in the development of DNA vaccines, can work together to quickly advance this novel vaccine technology into the clinic.

描述(由申请者提供)：这项资助计划是为发展安全有效的炭疽毒素疫苗而设。目前世界范围内在军事战区和普通民众中使用炭疽孢子作为生物恐怖武器的威胁使人们注意到需要一种更有效的炭疽疫苗。在过去的几个月里，人们认识到，医学界很少有人看到人类感染炭疽病，因此只有极少数人具备诊断和治疗炭疽病的能力。安全有效的预防性疫苗的提供将有效地消除这种形式的生物恐怖主义威胁。普赖斯等人已经证明，一种由编码解毒保护抗原(PA)和致死因子(LF)的质粒DNA组成的疫苗可以保护小鼠免受静脉注射的攻击，使用5倍的致死剂量的有毒蛋白。基于这项工作和随后的工作(这里介绍的)表明，类似的DNA疫苗接种方案可以保护兔子免受更严格的孢子吸入挑战，这笔赠款建议开展临床前工作，以支持DNA疫苗在人类临床试验中的测试。这项工作将推进FDA批准的编码PA或LF质粒的质粒DNA载体，或通过一系列实验方案来证明在小鼠和兔子中都能产生保护性免疫反应。这项建议的主旨是确定传递这些编码序列的最佳质粒，肌肉内传递的最佳配方，以及在大型哺乳动物中实现保护的最佳注射制度和剂量。这项工作证明了STTR资金的最佳使用。它将Vical公司与俄亥俄州立大学教授达雷尔·加洛韦博士结合在一起。Vical公司在过去12年里拥有先进的DNA疫苗接种技术，拥有制造DNA疫苗商业化产品所需的知识产权。达雷尔·加洛韦博士是一名研究人员，他推动了DNA疫苗对炭疽病的使用。该提案还介绍了拥有这些临床前实验所需的专业知识、动物设施和试剂的学术实验室以及一家小型生物技术公司开发DNA疫苗的专家如何共同努力，迅速将这项新的疫苗技术推向临床。